For research purposes only — not for human consumption.

CJC-1295 Chemistry: Structure-Activity Relationship and Half-Life Engineering Explained

CJC-1295 chemistry sits at the intersection of peptide science, receptor pharmacology, and protein-binding engineering — making it one of the most instructive examples of how modern researchers extend the biological activity of signaling peptides. At its core, CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), the endogenous 44-amino-acid peptide produced in the hypothalamus. What makes CJC-1295 remarkable as a research molecule is not simply what it does at the receptor level, but how its molecular architecture was deliberately engineered to resist degradation and bind circulating albumin — dramatically prolonging its functional half-life compared to the native hormone.

Key Takeaways

• CJC-1295 is a synthetic GHRH analogue comprising 30 amino acids, with several strategic substitutions that improve proteolytic stability.
• Its Drug Affinity Complex (DAC) technology — a maleimido-propionoyl (MPA) bioconjugate group — enables covalent binding to serum albumin, extending research half-life from minutes to days.
• The N-terminal tetrapeptide (Tyr-Ala-Asp-Ala) is the critical receptor-activation region; modifications elsewhere improve stability without disrupting this functional core.
• Preclinical studies suggest CJC-1295 activates the GHRH receptor (GHRHR), stimulating GH release from somatotroph cells via a Gs/adenylyl cyclase/cAMP pathway.
• Substitutions at positions 2, 8, and 15 — replacing labile amino acids — are the structural basis for its enhanced resistance to dipeptidyl peptidase IV (DPP-IV) and other proteases.
• Lyophilized CJC-1295 is stable when stored at -20°C and protected from moisture and light.

What Is GHRH, and Why Does Its Chemistry Matter?

To understand CJC-1295 chemistry, it helps to first appreciate its template. Native GHRH (also called GHRH 1-44-NH₂) is released in pulses from the hypothalamus and binds to GHRH receptors on pituitary somatotroph cells. The problem from a research standpoint is that endogenous GHRH has an extremely short plasma half-life — estimated at less than two minutes in some models — because it is rapidly cleaved by the enzyme dipeptidyl peptidase IV (DPP-IV) at the Ala²–Asp³ bond, and further degraded by serum proteases.

This rapid clearance makes GHRH itself poorly suited for extended mechanistic studies. Researchers needed a structurally modified analogue that preserved receptor affinity while surviving long enough in a biological environment to allow observation of downstream signaling events.

CJC-1295 Chemistry: The Molecular Blueprint

Sequence and Molecular Identity

CJC-1295 (with DAC) carries the systematic chemical name: Tat-GHRH(1-29)NH₂ modified with MPA-Lys at its C-terminus. Its amino acid backbone spans positions 1 through 29 of the native GHRH sequence (rather than the full 44 residues), because research on GHRH truncation established that the first 29 amino acids retain essentially full receptor binding and activation capacity.

• Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S (approximate; varies by source purity and salt form)
• Molecular weight: approximately 3647.28 Da (the peptide backbone alone, before DAC conjugation)
• Isoelectric point (pI): approximately 5.0–5.5, reflecting the relative abundance of acidic residues
• Appearance as lyophilized product: white to off-white powder

The peptide is typically produced via solid-phase peptide synthesis (SPPS) using Fmoc chemistry, allowing precise placement of non-natural amino acids at key positions.

Strategic Amino Acid Substitutions: The Structure-Activity Relationship

The structure-activity relationship (SAR) of CJC-1295 is where the real biochemical ingenuity lies. Four positions in the native GHRH sequence were deliberately altered:

Position 2 — Alanine replaces Asparagine Native GHRH carries an Asp at position 2. DPP-IV recognizes and cleaves the Ala¹–Asp² bond with high efficiency. By substituting Ala-2 with D-Alanine (a non-natural mirror-image amino acid), the cleavage recognition sequence is disrupted. DPP-IV cannot accommodate the D-configuration amino acid in its active site, so the peptide bond is protected from enzymatic attack — preserving the intact N-terminus that is critical for receptor engagement.

Position 8 — Substitution of a Methionine-vulnerable site Methionine residues are susceptible to oxidation under physiological conditions, which inactivates peptides and complicates long-duration research studies. At position 8 in some GHRH analogues, methionine is replaced with the isosteric leucine or norleucine to prevent oxidative degradation without meaningfully altering the side-chain geometry at the receptor interface.

Position 15 — Glutamine to Alanine Glutamine residues can undergo spontaneous deamidation — a hydrolytic reaction that converts Gln to Glu, introducing an unintended charge change and altering peptide conformation. The substitution at position 15 reduces this chemical liability, helping maintain structural consistency across the duration of a research experiment.

C-terminal amidation Rather than leaving a free carboxyl group at the C-terminus (position 29), CJC-1295 carries a C-terminal amide (-NH₂). Free carboxyl termini are recognition sites for carboxypeptidases; amidation blocks this cleavage and also mirrors the naturally amidated form of several endogenous neuropeptides, slightly improving receptor affinity at the GHRHR binding site.

Taken together, these four modifications constitute the SAR basis for CJC-1295's improved stability — none of them targeting the N-terminal pharmacophore (positions 1–4) where receptor activation is initiated.

The DAC Technology: Albumin-Binding Half-Life Extension

The most architecturally unique feature of CJC-1295 chemistry is the Drug Affinity Complex (DAC) moiety. DAC refers to a maleimido-propionoyl (MPA) chemical group conjugated to a lysine residue appended at the C-terminus of the peptide. Understanding its chemistry requires a brief detour into protein biochemistry.

Serum Albumin as a Half-Life Vehicle

Human serum albumin (HSA) is the most abundant circulating protein in plasma, present at roughly 35–50 g/L. It is well-known as a transporter of fatty acids, hormones, and small molecules. Critically for half-life engineering, albumin itself has a circulating half-life of approximately 19–21 days because it undergoes FcRn-mediated (neonatal Fc receptor) recycling, escaping lysosomal degradation.

If a research peptide can bind stably to albumin, it effectively "borrows" albumin's prolonged half-life.

The Michael Addition Reaction

The maleimide group on the MPA linker undergoes a thiol-selective Michael addition reaction with the free thiol (–SH) group on the cysteine-34 residue of albumin — the single free cysteine present on the protein. This reaction:

1. Is covalent and essentially irreversible under physiological conditions
2. Occurs in situ — meaning once CJC-1295 is present in a biological milieu, it binds albumin spontaneously
3. Does not alter the N-terminal pharmacophore, leaving receptor-binding capacity intact

The result is that the peptide circulates as an albumin–CJC-1295 complex. Preclinical pharmacokinetic studies in animal models suggest a plasma half-life for this complex on the order of days rather than minutes, an extension of roughly 100–1000-fold compared to native GHRH — representing one of the most dramatic half-life engineering successes reported in synthetic peptide chemistry.

Receptor-Level Mechanism of Action: From Binding to Signal Cascade

CJC-1295 engages the GHRH receptor (GHRHR), a class B G-protein-coupled receptor (GPCR) expressed predominantly on pituitary somatotroph cells. The signaling cascade proceeds through well-characterized steps:

1. Ligand binding: The N-terminal region of CJC-1295 (particularly the Tyr¹-Ala²-Asp³-Ala⁴ tetrapeptide) engages the extracellular domain and transmembrane helices of GHRHR, inducing a conformational change.
2. G-protein activation: The receptor couples to the stimulatory α-subunit of G-protein (Gαs), catalyzing GTP exchange.
3. Adenylyl cyclase stimulation: Active Gαs binds and activates membrane-bound adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) production.
4. PKA activation: cAMP activates Protein Kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP Response Element-Binding protein).
5. GH gene transcription and secretion: CREB phosphorylation upregulates GH gene expression; concurrently, elevated cAMP also facilitates calcium-dependent exocytosis of pre-formed GH granules from somatotroph cells.

Preclinical research in rodent models suggests that GHRHR agonism by CJC-1295 produces pulsatile-pattern GH secretion consistent with physiological rhythms rather than a flat, sustained elevation — a distinction attributed to the preserved pulsatile feedback architecture of the hypothalamic-pituitary axis.

Comparing CJC-1295 With and Without DAC: Mechanistic Distinctions

It is important, from a research chemistry standpoint, to distinguish two versions of this molecule:

The without-DAC version relies entirely on the four SAR substitutions described above for its improved (but still relatively short) stability. Both versions activate the same Gαs/cAMP pathway — the distinction lies purely in pharmacokinetic half-life chemistry, not in receptor-level mechanism.

Lyophilized Storage Considerations

For research applications, CJC-1295 is supplied as a lyophilized (freeze-dried) powder. In this dry, solid state, the peptide is chemically stable. Long-term storage of the unopened lyophilized product at -20°C, away from repeated freeze-thaw cycling, light exposure, and moisture, is recommended to preserve structural integrity for experimental use.

Frequently Asked Questions

Q1: Why does CJC-1295 only use positions 1–29 of the native GHRH sequence rather than the full 44 residues? Structure-activity relationship research on GHRH truncation analogues — pioneered in the 1980s and 1990s — demonstrated that GHRHR binding and full agonist activity is retained by the first 29 amino acids. Residues 30–44 appear to contribute minimally to receptor affinity, and their removal simplifies synthesis while reducing molecular weight and potential immunogenic surface area.

Q2: What makes the maleimide-thiol Michael addition reaction so specific for albumin's Cys-34? Cys-34 is the only free (reduced, unoxidized) cysteine on human serum albumin. The other cysteine residues on albumin are engaged in disulfide bridges. Because maleimides react selectively with free thiols at physiological pH — rather than with amines, which would require more alkaline conditions — the Michael addition chemistry is inherently selective for this single reactive site on albumin.

Q3: How does DPP-IV recognize and cleave peptides, and why does D-Ala at position 2 prevent this? DPP-IV (dipeptidyl peptidase IV, also known as CD26) is a serine protease that cleaves the penultimate peptide bond from the N-terminus when a proline or alanine residue occupies position 2. Its active site has a stereospecific substrate-binding pocket that accommodates only L-configuration amino acids. Introducing D-Alanine at position 2 presents the wrong stereochemistry to the enzyme, preventing productive substrate binding and blocking cleavage.

Q4: Is the Gαs/cAMP/PKA/CREB pathway unique to GHRHR, or do other receptors use the same cascade? This signaling pathway is not unique to GHRHR — it is a broadly conserved mechanism used by many class B GPCRs and some class A GPCRs, including glucagon receptors, VIP receptors, and β-adrenergic receptors. What distinguishes GHRHR signaling is its expression pattern (highly enriched on pituitary somatotrophs) and the downstream transcriptional and secretory targets (primarily GH gene promoter elements), which gives the pathway its tissue-specific functional outcomes.

Q5: How was CJC-1295 discovered, and what was the historical research context? CJC-1295 was developed in the early 2000s by ConjuChem Biotechnologies (Montreal, Canada), building on decades of GHRH analogue chemistry initiated by researchers including Andrew Schally and Roger Guillemin — who shared the 1977 Nobel Prize in Physiology or Medicine for their work on hypothalamic peptide hormones. ConjuChem applied its proprietary DAC platform — originally developed for insulin analogues — to the Mod-GRF 1-29 backbone, producing what they designated CJC-1295. Early preclinical work reported in peer-reviewed journals through the mid-2000s documented its albumin-binding kinetics and in vivo GH stimulation profiles in animal models.

Q6: Does albumin conjugation change how CJC-1295 interacts with the GHRH receptor at the molecular level? Preclinical research suggests the albumin-conjugated complex retains functional GHRHR agonism. The MPA linker and albumin mass are attached at the C-terminus (position 29), which is distant from the N-terminal pharmacophore (positions 1–4) responsible for receptor activation. Crystallographic and computational modeling studies of GHRHR–ligand interactions suggest the receptor's binding groove accommodates the peptide's N-terminal domain independent of C-terminal modifications — though the albumin molecule itself (at ~66 kDa) is too large to enter the binding cleft and likely dissociates from the peptide during receptor engagement.

For research purposes only — not for human consumption.